On December 20, 2021, the FDA approved Apretude® (cabotegravir extended-release injectable suspension) for at-risk individuals weighing at least 77 pounds for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus (HIV). The efficacy of PrEP treatment relies on high levels of adherence, which may be difficult to achieve with current daily oral treatment options. Apretude® treatment is initiated via two injections, one month apart, followed by one injection every two months thereafter. Treatment may also be initiated using oral cabotegravir followed by one injection of Apretude® at months one and two, respectively, followed by one injection every two months thereafter. The approval was granted following positive results from two randomized, double-blind clinical trials that compared injectable Apretude® to Truvada®, an oral HIV PrEP treatment taken once daily. The first trial enrolled 4,556 cisgender men and transgender women who have sex with men, randomized to receive treatment with either Apretude® or Truvada®. Participants who received Apretude® had a 69% less chance of getting infected with HIV when compared to the Truvada® group. Trial 2 enrolled 3,224 cisgender women and found that those who took Apretude® had a 90% less chance of getting infected with HIV when compared to Truvada®. Side effects from Apretude® include injection site reactions, headache, fever, fatigue, back pain, rash, and muscle aches and pain. A negative HIV test should be obtained prior to each injection of Apretude® in order to reduce the risk of developing drug-resistant HIV variants. Individuals who have a history of less than desirable adherence to the daily oral PrEP regimens may stand to benefit from long-acting injectable medications such as Apretude®.